Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3023-3031

  Herynk, Matthew H ^a   Beyer, Amanda R ^a   Cui, Yukun ^a   Weiss, Heide ^a   Anderson, Elizabeth ^b   Green, Tim P ^b   Fuqua, Suzanne A W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 0530; ESTROGEN; ESTROGEN RECEPTOR ALPHA; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METASTASIS; ONCOGENE SRC; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WILD TYPE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIOXOLES; BREAST NEOPLASMS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ESTROGEN RECEPTOR ALPHA; ESTROGENS; HUMANS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; TAMOXIFEN;

EID: 33846235881     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0394     Document Type: Article

References (36)

1. Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia 1997;2:323-34.
2. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-α (Eα) and estrogen receptor-Β(ERβ) messenger ribonucleic acid in the wild-type and ERα-knockout mouse. Endocrinology 1997; 138:4613-21.
3. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
4. Speirs V, Parkes AT, Kerin MJ, et al. Coexpression of estrogen receptor α and β: poor prognostic factors in human breast cancer? Cancer Res 1999;59:525-8.
5. Fuqua SA, Wiltschke C, Zhang QX, et al. A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res 2000;60: 4026-9.
6. Conway K, Parrish E, Edmiston SN, et al. The estrogen receptor-α. A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res 2005;7: R871-80.
7. Wang C, Fu M, Angeletti RH, et al. Direct acetylation of the estrogen receptor α hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem 2001;276:18375-83.
8. Cui Y, Zhang M, Pestell R, Curran EM, Welshons WV, Fuqua SA. Phosphorylation of estrogen receptor a blocks its acetylation and regulates estrogen sensitivity. Cancer Res 2004;64:9199-208.
9. Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-98.
10. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58.
11. Reissig D, Clement J, Sanger J, Berndt A, Kosmehl H, Bohmer FD. Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue. J Cancer Res Clin Oncol 2001;127:226-30.
12. Rosen N, Bolen JB, Schwartz AM, Cohen P, DeSeau V, Israel MA. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 1986;261:13754-9.
13. Webster MA, Cardiff RD, Muller WJ. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. Proc Natl Acad Sci U S A 1995;92:7849-53.
14. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994;8:23-32.
15. Migliaccio A, Pagano M, Auricchio F. Immediate and transient stimulation of protein tyrosine phosphorylation by estradiol in MCF-7 cells. Oncogene 1993;8:2183-91.
16. Castoria G, Migliaccio A, Bilancio A, et al. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J 200 1; 20:6050-9.
17. Migliaccio A, Di Domenico M, Castoria G, et al. Tyrosine kinase/p21ras/ MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996; 15:1292-300.
18. Haynes MP, Li L, Sinha D, et al. Src kinase mediates phosphatidylinositol 3-kinase/Akt-dependent rapid endothelial nitric-oxide synthase activation by estrogen. J Biol Chem 2003;278:2118-23.
19. Arnold SF, Obourn JD, Jaffe H, Notides AC. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 1995;9:24-33.
20. Ple PA, Green TP, Hennequin LF, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 2004;47: 871-87.
21. Laska EM, Meisner M, Siegel C. Simple designs and model-free tests for synergy. Biometrics 1994;50:834-41.
22. Herynk MH, Stoeltzing O, Reinmuth N, et al. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 2003;63:2990-6.
23. Oesterreich S, Zhang P, Guler RL, et al. Re-expression of estrogen receptor α in estrogen receptor α-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Res 200 1;61:5771-7.
24. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001;20:1465-75.
25. Rahimi N, Hung W, Tremblay E, Saulnier R, Elliott B. c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J Biol Chem 1998;273:33714-21.
26. Hiscox S, Morgan L, Green TP, Barrow D, Gee J, Nicholson RI. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006;97:263-74.
27. Barletta F, Wong CW, McNally C, Komm BS, Katzenellenbogen B, Cheskis BJ. Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 2004; 18:1096-108.
28. Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ. Estrogen receptor- interacting protein that modulates its nongenomic activity-cross-talk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A 2002;99:14783-8.
29. Harms C, Lautenschlager M, Bergk A, et al. Differential mechanisms of neuroprotection by 17β-estradiol in apoptotic versus necrotic neurodegeneration. J Neurosci 2001;21:2600-9.
30. Sawada H, Ibi M, Kilhara T, et al. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J 2000;14: 1202-14.
31. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 2003;4:46-56.
32. Ho WC, Uniyal S, Zhou H, Morris VL, Chan BM. Threshold levels of ERK activation for chemotactic migration differ for NGF and EGF in rat pheochromocytoma PC12 cells. Mol Cell Biochem 2005;271: 29-41.
33. Castoria G, Barone MV, Di Domenico M, et al. Non-transcriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J 1999; 18:2500-10.
34. Gaben AM, Saucier C, Bedin M, Redeuilh G, Mester J. Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinosital 3-kinase. Mol Endocrinol 2004; 18:2700-13.
35. Acconcia F, Barnes CJ, Kumar R. Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 2006; 147:1203- 12.
36. Groten T, Pierce AA, Huen AC, Schnaper HW. 17 β-Estradiol transiently disrupts adherens junctions in endothelial cells. FASEB J 2005; 19:1368-70.